BioMarin Pharmaceuticals BMRN Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax.
The official record: BioMarin Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioMarin Pharmaceuticals's debt securities, available-for-sale, accumulated gross unrealized loss, before tax.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioMarin Pharmaceuticals's debt securities, available-for-sale, accumulated gross unrealized loss, before tax?
- BioMarin Pharmaceuticals (BMRN) reported debt securities, available-for-sale, accumulated gross unrealized loss, before tax of $0 in Q1 2026.
- How has BioMarin Pharmaceuticals's debt securities, available-for-sale, accumulated gross unrealized loss, before tax changed year-over-year?
- BioMarin Pharmaceuticals's debt securities, available-for-sale, accumulated gross unrealized loss, before tax decreased by 100.0% year-over-year, from $245K to $0.
- What is the long-term trend for BioMarin Pharmaceuticals's debt securities, available-for-sale, accumulated gross unrealized loss, before tax?
- Over 5 years (2020 to 2025), BioMarin Pharmaceuticals's debt securities, available-for-sale, accumulated gross unrealized loss, before tax has grown at a -6.2% compound annual growth rate (CAGR), from $11K to $8K.